News/ News/ News/ Oncology/ R&D Regeneron seeks CheckMate in immuno-oncology play Phil Taylor CheckMate Pharma, head and neck cancer, immuno-oncology, M&A, melanoma, Oncology, Regeneron, toll-like receptor agonist, vidutolimod 0 Comment Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy Share X Regeneron seeks CheckMate in immuno-oncology play https://pharmaphorum.com/news/regeneron-seeks-checkmate-in-immuno-oncology-play/